BWXT Sells Medical Unit to Nordic Capital for Up to $800M
Event summary
- BWXT selling its medical business to Nordic Capital for up to $800M, including BWXT Medical and Kinectrics’ stable medical isotopes business.
- Transaction expected to close by the end of 2026, subject to regulatory approvals.
- BWXT will maintain a minority ownership stake in the divested business and continue providing specialized isotope and radiochemical expertise under the agreement.
- Nordic Capital plans to scale the business and expand access to cutting-edge radiopharmaceutical therapy.
The big picture
BWXT’s divestiture reflects a broader trend of companies streamlining operations to focus on core competencies, particularly in high-growth sectors like nuclear security. Nordic Capital’s acquisition underscores private equity’s appetite for specialized healthcare assets, especially those with scalable radiopharmaceutical capabilities. The $800M deal size highlights the strategic value of BWXT’s medical unit, despite its divestiture.
What we're watching
- Strategic Focus
- Whether BWXT can successfully redirect resources to accelerate growth in its core nuclear national security and commercial nuclear power markets.
- Execution Risk
- The pace at which Nordic Capital can scale the medical business and expand its market presence in radiopharmaceuticals.
- Regulatory Approvals
- How quickly the transaction receives necessary regulatory approvals and closes by the end of 2026.
Related topics